Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amena Deluca

MOHS-Micrographic Surgery Phoenix, AZ Medical Doctor

NPI 1972766921 CMS profile 225074

4512 N 40Th St, Phoenix, AZ 85018

Open in the dashboard

General payments

$5,538

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amena Deluca of Phoenix, AZ is reported in the CMS Open Payments database as having received $5,538 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,328 85
2024 General $2,084 78
2023 General $611 18
2022 General $186 3
2019 General $330 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amena Deluca
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Amena Deluca were reported at $2,328. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Amena Deluca MOHS-Micrographic Surgery median Middle half National median
2019 $330 $316 $106–$785 $163
2020 $0 $162 $68–$412 $114
2021 $0 $243 $87–$654 $132
2022 $186 $300 $102–$887 $149
2023 $611 $364 $125–$1,010 $160
2024 $2,084 $445 $142–$1,108 $164
2025 $2,328 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $701 25 payments
  2. Genzyme Corporation $532 16 payments
  3. Sun Pharmaceutical Industries Inc. $358 12 payments
  4. Regeneron Healthcare Solutions, Inc. $350 13 payments
  5. Galderma Laboratories, L.P. $307 7 payments
  6. Incyte Corporation $303 10 payments
  7. Janssen Biotech, Inc. $257 11 payments
  8. Amgen Inc. $210 5 payments
  9. UCB, Inc. $210 9 payments
  10. Dermavant Sciences, Inc. $207 9 payments
  11. Other $2,103 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,538 189 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $557 17 payments
  2. SKYRIZI $514 15 payments
  3. VTAMA $318 15 payments
  4. OPZELURA $303 10 payments
  5. TREMFYA $257 11 payments
  6. Winlevi $242 7 payments
  7. Otezla $210 5 payments
  8. Bimzelx $210 9 payments
  9. DAXXIFY $201 4 payments
  10. LIBTAYO $186 8 payments
  11. Other $2,118 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

305

Median for Dermatology: 534

Drug cost

$3,073

Median for Dermatology: $67,151

Branded share of claims

14.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 150 $952
Valacyclovir Valacyclovir Hcl Brand 43 $700
Hydroxychloroquine Sulfate Generic 13 $421
Mupirocin Generic 50 $345
Clobetasol Propionate Generic 12 $328
Triamcinolone Acetonide Generic 20 $172
Doxycycline Hyclate Generic 17 $154

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 104 billing codes

Paid by Medicare

$1,198,659

Of which drugs: $112,289

Medicare patients

1,691

Average age 75

Services billed

16,514

942 women, 749 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 42%
Ischemic heart disease 24%
Osteoporosis 18%
Cancer 17%
Chronic kidney disease 16%
Atrial fibrillation 15%
Diabetes 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 77 94 $29,083
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 28 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $236
$236 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $183
$183 — —
VTAMA
  • Dermavant Sciences, Inc. $166
$166 — —
TREMFYA
  • Janssen Biotech, Inc. $108
$108 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record